GlaxoSmithKline plc’s Short-Term Pain Could Be Investors’ Long-Term Gain

GlaxoSmithKline plc (LON: GSK) is well placed for long-term growth.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) shares have taken a beating during the past year or so, as allegations of bribery have hit the company’s Chinese arm, where sales have slumped as a result.

What’s more, fresh allegations of bribery have arisen during the past two weeks with Glaxo now suspected of bribing officials within Jordan, Lebanon, Iraq and Poland in order to drive sales.gsk

Unsurprisingly, the market has not taken this news well and, up until today, investors were dumping Glaxo’s shares, sending them to a 52-week low.

However, for the long-term investor, this could be a great buying opportunity.

You see, while investors may be unimpressed with Glaxo’s actions now, it is likely that over the next few months the market will forgive the company. Indeed, as one of the world’s leading pharmaceutical companies, with an exclusive portfolio of treatments, Glaxo’s customers are unlikely to turn their back on the company for a sustained period of time.

As a result, although Glaxo’s sales may decline in some markets as a result of bribery claims in the near term, over the longer term the company’s sales should recover. 

Changing practices

Still, Glaxo’s management knows the company has made some mistakes. So, management is making drastic changes to the way Glaxo markets products to prospective customers.

For example, management has overhauled company marketing practices within the United States, changing the way sales representatives are paid and ending a plan whereby doctors were paid by the company to speak at industry events. 

Good news

On the other hand however, during the past week Glaxo has announced that two of its new treatments have been approved for sale. With these two new products hitting the market, Glaxo has brought a total of seven new drugs to market within the past 16 months.

And this is not taking into account today’s game-changing deal between Glaxo and Swiss drugs producer Novartis.

Specifically, the deal with Novartis will see the consumer divisions of Glaxo and Novartis merge, creating a ‘world-leading’ consumer healthcare business with £6.5bn in revenue in 2013. In addition, Glaxo is acquiring Novartis’ vaccines business for an initial cash consideration of $5.25bn and Novartis is acquiring Glaxo’s oncology portfolio for $14.5bn.

Foolish summary

So overall, bribery allegations made against Glaxo may dent the company’s sales in the short term. However, Glaxo’s dominance within the global pharmaceutical market implies that over the long term, sales will recover, making the company look like a great investment at current levels. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in GlaxoSmithKline. 

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

3 UK stocks I reckon could benefit from the upcoming general election

As the general election hurtles towards us, this Fool wonders which UK stocks could benefit, and focuses on three picks…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

At 11%, this dividend share pays the biggest yield in the FTSE 100

When a dividend share offers a big yield, we need to be cautious of the risks. But I reckon this…

Read more »

British Isles on nautical map
Investing Articles

I reckon Hiscox shares could be one of the best bargains on the FTSE

I've been investing in FTSE companies for years, but after a major decline I've not seen a company with as…

Read more »

Grey Number 4 Stencil on Yellow Concrete Wall
Investing Articles

4 reasons I’d still buy National Grid shares in a heartbeat despite the recent wobble!

As National Grid shares plunged on the news of a right issue, I’m not flinching, and reckon it's a top…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

After gaining 45% in 12 months, is the Amazon share price now overvalued?

Our author thinks the Amazon share price might be too high. While the long-term future of the business looks bright,…

Read more »

Investing Articles

2 hot dividend stocks I’d buy and hold for 10 years

Our writer reckons these two dividend stocks could help her bag juicy dividends for years to come and explains why.

Read more »

British Pennies on a Pound Note
Investing Articles

2 dividend-paying penny shares I’d happily own

These two penny shares have caught our writer's eye for a combination of income prospects now and business growth potential…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This FTSE 250 share looks like a bargain to me!

This FTSE 250 share has seen its price tumble due to chaotic local economic conditions in a key market. But…

Read more »